A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT07258511

Public ClinicalTrials.gov record NCT07258511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody

Study identification

NCT ID: NCT07258511
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

JNJ-79635322 Drug
Teclistamab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 3, 2026
Primary completion: Dec 11, 2028
Completion: Sep 29, 2031
Last update posted: Apr 12, 2026

2026 – 2031

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
USC Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
University of Connecticut Health Center	Farmington	Connecticut	06030	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
Florida Cancer Specialists & Research Institute	Fort Myers	Florida	33901	Recruiting
Emory University	Atlanta	Georgia	30322	Recruiting
University of Iowa Hospital and Clinics	Iowa City	Iowa	52242	Recruiting
Mission Cancer Blood	Waukee	Iowa	50263	Recruiting
Norton Cancer Institute	Louisville	Kentucky	40207	Recruiting
Mount Sinai Brooklyn	Brooklyn	New York	11234	Recruiting
Mount Sinai Chelsea	New York	New York	10011	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Durham VAMC	Durham	North Carolina	27705	Recruiting
Oregon Health And Science University	Portland	Oregon	97239	Recruiting
Thomas Jefferson University Hospital	Philadelphia	Pennsylvania	19107	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07258511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07258511 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →